Mineralys Therapeutics CEO Jon Congleton Sells $1.9M in MLYS Shares

Mineralys Therapeutics CEO Jon Congleton sold 75,000 shares of company stock on September 30, 2026, totaling approximately $1.9 million. The transaction occurs as the biotechnology firm advances toward a potential commercial launch for its lead hypertension candidate, lorundrostat.

"The stock sales were executed pursuant to a Rule 10b5-1 trading plan adopted by Mr. Congleton on December 23, 2025," according to an insider trading disclosure.

Understanding Rule 10b5-1 Trading Plans

Corporate insiders often utilize Rule 10b5-1 plans to mitigate concerns regarding potential conflicts of interest or the use of non-public information. These plans allow executives to establish a pre-arranged schedule for selling shares at predetermined times or prices. By adopting the plan months in advance, specifically in December 2025, executives demonstrate that their trading activity is automated and not based on current market fluctuations or pending clinical developments.

Following the completion of this sale, Mr. Congleton maintains a stake in the company, holding direct beneficial ownership of 528,621 shares of Mineralys Therapeutics common stock.

Regulatory Timeline for Lorundrostat

The sale occurs as Mineralys Therapeutics navigates the final stages of the regulatory process. The company's lead drug candidate, lorundrostat, is currently under FDA review. Management has indicated that a potential commercial launch for the hypertension treatment is anticipated in late 2026 or early 2027, pending final regulatory approval.

For investors and stakeholders, the regulatory outcome remains the primary driver of the company's valuation. The transition from a clinical-stage entity to a commercial-stage firm involves operational scaling, and the upcoming FDA decision is a factor for the organization's long-term growth strategy.